Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Yi Li, Chengcheng Gong, Qianyi Lu, Zhaochun Zhou, Ting Luo, Wei Li, Gang Li, Rui Ge, Fei Xu, Biyun Wang, Yi Li, Chengcheng Gong, Qianyi Lu, Zhaochun Zhou, Ting Luo, Wei Li, Gang Li, Rui Ge, Fei Xu, Biyun Wang

Abstract

Introduction: Combination of trastuzumab (T) and lapatinib (L) has been showed to significantly improve the prognosis of HER2+ heavily pretreated metastatic breast cancer (MBC). Whether TL combined chemotherapy (TLC) can further improve the efficacy in HER2+ MBC remains to be further studied. The aim of the study was to report the first real-world data of TLC in HER2+ MBC, including the efficacy, safety and treatment patterns. Methods: Patients with HER2+ MBC treated with TLC in 5 institutions of China from September 2013 to July 2019 were included. Progression free survival (PFS), objective response rate (ORR), overall survival (OS), toxicity profile and treatment pattern were reported. Results: A total of 285 patients were included. 88.8% were exposed to trastuzumab and 49.2% received 2 or more lines of systematic therapy before TLC previously. The most common chemotherapy regimens combined with TL were capecitabine (40.7%) and vinorelbine (21.4%) and almost 1/3 received maintenance treatment after TLC. Median PFS was 10.9 months while patients received TLC as first line treatment showed longest median PFS of 20.7 months. Patients pretreated with trastuzumab showed a median PFS of 10.2 months. In patients who pretreated with trastuzumab, the continuation of trastuzumab on the basis of standard lapatinib plus capecitabine had a median PFS of 11.3 months. TL combined with capecitabine or vinorelbine showed no significant difference in median PFS, though TL combined with capecitabine had numerically prolongation (11.4 vs. 8.5 months, p = 0.231). Patients had brain metastasis (BM) also showed a median PFS (intracranial and extracranial lesions considered) of 10.6 months. Lines of systematic metastatic treatment was an independent predictive factor of PFS. The median OS was not reached. Two hundred and seventy seven patients were included in ORR analysis. ORR was 42.6%. Toxicities of triplet combinations were tolerable and the most common grade 3 and 4 adverse events were neutropenia (16.8%). Conclusions: TLC demonstrated promising effects and tolerable safety in HER2+MBC, even in patients with BM, providing a theoretical basis for clinical practice. Clinical Trial Registration: ClinicalTrials.gov, Identifier: NCT04001634.

Keywords: chemotherapy; human epidermal growth factor receptor 2 positive; lapatinib; metastatic breast cancer; trastuzumab.

Copyright © 2020 Li, Gong, Lu, Zhou, Luo, Li, Li, Ge, Xu and Wang.

Figures

Figure 1
Figure 1
Kaplan-Meier curve of progression free survival (A) for all patients and patients stratified by treatment lines (B).
Figure 2
Figure 2
Kaplan-Meier curve of progression free survival for patients pretreated with trastuzumab.
Figure 3
Figure 3
Kaplan-Meier curve of progression free survival for patients received TLX after progressing on trastuzumab.
Figure 4
Figure 4
Kaplan–Meier curve of progression free survival of patients treated with TL plus capecitabine or vinorelbine.
Figure 5
Figure 5
Kaplan-Meier curve of progression free survival in patients with brain metastasis.
Figure 6
Figure 6
Kaplan-Meier curve of progression free survival for patients with and without previous lapatinib.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492
    1. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. (2019) 321:288–300. 10.1001/jama.2018.19323
    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. (2001) 344:783–92. 10.1056/NEJM200103153441101
    1. Bartsch R, Wenzel C, Zielinski CC, Steger GG. HER-2-positive breast cancer: hope beyond trastuzumab. Biodrugs. (2007) 21:69–77. 10.2165/00063030-200721020-00001
    1. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. (2006) 8:215. 10.1186/bcr1612
    1. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. (2006) 355:2733–43. 10.1056/NEJMoa064320
    1. Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, et al. . Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist. (2010) 15:799–809. 10.1634/theoncologist.2009-0029
    1. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. . Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. (2009) 27:1999–2006. 10.1200/JCO.2008.19.6618
    1. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, et al. . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. (2009) 28:803–14. 10.1038/onc.2008.432
    1. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. . Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. (2010) 28:1124–30. 10.1200/JCO.2008.21.4437
    1. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. . Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. (2012) 30:2585–92. 10.1200/JCO.2011.35.6725
    1. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. . Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer. N Engl J Med. (2017) 377:122–31. 10.1056/NEJMoa1703643
    1. Crown J, Kennedy MJ, Tresca P, Marty M, Espie M, Burris HA, et al. . Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol. (2013) 24:2005–11. 10.1093/annonc/mdt222
    1. Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, et al. . An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist. (2013) 18:661–6. 10.1634/theoncologist.2012-0129
    1. Ales-Martinez JE, Filipovich E, Garcia Llano JL, Ceballos Viro J, Sanchez-Escribano R. Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients. J Clin Oncol. (2014) 32(Suppl. 15):e11513 10.1200/jco.2014.32.15_suppl.e11513
    1. Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C, et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2+ metastatic breast cancer. Oncologist. (2011) 16:1535–46. 10.1634/theoncologist.2011-0165
    1. Gavila J, De La Haba J, Bermejo B, Rodriguez-Lescure A, Anton A, Ciruelos E, et al. . A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. Clin Transl Oncol. (2020) 22:420–8. 10.1007/s12094-019-02145-4
    1. Xu B, Li W, Zhang Q, Shao Z, Jia WX, Li H, et al. A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) plus trastuzumab (H) plus docetaxel (0) versus Pla plus H plus D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN). J Clin Oncol. (2019) 37(Suppl. 15):1026 10.1200/JCO.2019.37.15_suppl.1026
    1. Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, et al. . A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Cancer Biol Ther. (2019) 20:192–200. 10.1080/15384047.2018.1523095
    1. Gomez HL, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, et al. . A phase ii randomized study of lapatinib combined with capecitabine, vinorelbine, or gemcitabine in patients with HER2-positive metastatic breast cancer with progression after a taxane (Latin American cooperative oncology group 0801 study). Clin Breast Cancer. (2016) 16:38–44. 10.1016/j.clbc.2015.10.005
    1. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. . Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. (2008) 26:1993–9. 10.1200/JCO.2007.12.3588
    1. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. . Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. (2013) 14:64–71. 10.1016/S1470-2045(12)70432-1
    1. Petrelli F, Ghidini M, Lonati V, Tomasello G, Borgonovo K, Ghilardi M, et al. . The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis. Eur J Cancer. (2017) 84:141–8. 10.1016/j.ejca.2017.07.024
    1. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. . Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. (2011) 17:4834–43. 10.1158/1078-0432.CCR-10-2962
    1. Yap YS, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, et al. . Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. (2012) 107:1075–82. 10.1038/bjc.2012.346

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel